Patents Assigned to Neuralstem, Inc.
  • AMELIORATION OF COGNITIVE AND MOTOR DEFICITS ASSOCIATED WITH ALZHEIMER'S
    Publication number: 20210106579
    Abstract: Cognitive and/or motor deficiencies associated with Alzheimer's are treated using 2-amino substituted nicotinamides on their pharmaceutically acceptable salts.
    Type: Application
    Filed: May 17, 2019
    Publication date: April 15, 2021
    Applicant: Neuralstem, Inc.
    Inventor: Karl K. JOHE
  • Stable neural stem cells comprising an exogenous polynucleotide coding for a growth factor and methods of use thereof
    Patent number: 10702555
    Abstract: The present disclosure provides a human neural stem cell comprising an exogenous polynucleotide coding for a growth factor such as IGF-1. Also disclosed are methods of using the human neural stem cells for the treatment of neurodegenerative diseases or disorders including, for example, ALS.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: July 7, 2020
    Assignee: NEURALSTEM, INC.
    Inventors: Thomas Hazel, Karl K. Johe
  • Amelioration of certain deficiencies due to stroke
    Patent number: 10413534
    Abstract: Motor skill deficits and cognitive deficits associated with stroke and secondary neuronal cell death are ameliorated by treatment with pharmaceutically acceptable salts of 2-amino substituted nicotinamides.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: September 17, 2019
    Assignee: NEURALSTEM, INC.
    Inventor: Karl K. Johe
  • Amelioration of neural deficits associated with diabetes
    Patent number: 10322115
    Abstract: Methods for treating non-systemic deficiencies associated with diabetes using 2-amino substituted nicotinamides or their pharmaceutically acceptable salts.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: June 18, 2019
    Assignee: Neuralstem, Inc.
    Inventor: Karl K. Johe
  • AMELIORATION OF ANGELMAN'S SYNDROME DEFICIENCIES
    Publication number: 20190142829
    Abstract: Treatment with 2-amino substituted nicotinamides or their salts ameliorates the cognitive and motor dysfunction associated with Angelman Syndrome (AS).
    Type: Application
    Filed: April 24, 2018
    Publication date: May 16, 2019
    Applicant: Neuralstem, Inc.
    Inventor: Karl K. JOHE
  • Methods of treating neurodegenerative conditions
    Patent number: 10286010
    Abstract: The invention relates generally to methods of treating spasticity, rigidity, or muscular hyperactivity conditions by introducing a portion of an expanded population of neural stem cells into an area of a recipient spinal cord.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: May 14, 2019
    Assignee: Neuralstem, Inc.
    Inventors: Karl K. Johe, Thomas G. Hazel, Martin Marsala, Osamu Kakinohana
  • AMELIORATION OF CERTAIN DEFICIENCIES DUE TO STROKE
    Publication number: 20180228787
    Abstract: Motor skill deficits and cognitive deficits associated with stroke and secondary neuronal cell death are ameliorated by treatment with pharmaceutically acceptable salts of 2-amino substituted nicotinamides.
    Type: Application
    Filed: February 13, 2018
    Publication date: August 16, 2018
    Applicant: NEURALSTEM, INC.
    Inventor: Karl K. JOHE
  • AMELIORATION OF RADIATION-INDUCED COGNITIVE DYSFUNCTION
    Publication number: 20180104240
    Abstract: Treatment with 2-amino substituted nicotinamides ameliorates the cognitive dysfunction resulting from radiation of the brain.
    Type: Application
    Filed: October 18, 2017
    Publication date: April 19, 2018
    Applicant: NEURALSTEM, INC.
    Inventor: Karl K. JOHE
  • AMELIORATION OF NEURAL DEFICITS ASSOCIATED WITH DIABETES
    Publication number: 20180071267
    Abstract: Methods for treating non-systemic deficiencies associated with diabetes using 2-amino substituted nicotinamides or their pharmaceutically acceptable salts.
    Type: Application
    Filed: September 12, 2017
    Publication date: March 15, 2018
    Applicant: Neuralstem, Inc.
    Inventor: Karl K. JOHE
  • Stable neural stem cells comprising an exogenous polynucleotide coding for a growth factor and methods of use thereof
    Patent number: 9750769
    Abstract: The present disclosure provides a human neural stem cell comprising an exogenous polynucleotide coding for a growth factor such as IGF-1. Also disclosed are methods of using the human neural stem cells for the treatment of neurodegenerative diseases or disorders including, for example, ALS.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: September 5, 2017
    Assignee: Neuralstem, Inc.
    Inventors: Thomas Hazel, Karl K. Johe
  • Methods of treating ischemic spasticity
    Patent number: 9744194
    Abstract: The invention relates generally to methods of treating spasticity, rigidity, or muscular hyperactivity conditions by introducing a portion of an expanded population of neural stem cells into an area of a recipient spinal cord.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: August 29, 2017
    Assignees: Neuralstem, Inc., The Regents of the University of California
    Inventors: Karl K. Johe, Thomas G. Hazel, Martin Marsala, Osamu Kakinohana
  • Protocols for treatment of major depressive disorder (MDD)
    Patent number: 9572807
    Abstract: Although it is known that certain benzylpiperazine-aminopyridines or open chain forms thereof are effective in stimulating neural growth in in vitro tests, it has now been surprisingly found that administering these compounds in a dosage range of 10 mg/day-130 mg/day over 25-35 days is effective in treating Major Depressive Disorder (MDD) such that statistically significant results can be obtained with samples of only six subjects.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: February 21, 2017
    Assignee: Neuralstem, Inc.
    Inventor: Karl K. Johe
  • Methods for treating and/or reversing neurodegenerative diseases and/or disorders
    Patent number: 9540611
    Abstract: The present disclosure provides methods for the treatment of neurological diseases/disorders using neural stem cells (NSCs) obtained from a spinal cord tissue. The methods may include the use of a NSC population to treat a neurological disease/disorder of the brain. Such methods may include introducing exogenously cultured and expanded NSCs into the brain, which differentiate into neurons capable of integrating in vivo into the brain tissue in a sufficient manner to ameliorate the symptoms associated with the neurological disease/disorder.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: January 10, 2017
    Assignee: Neuralstem, Inc.
    Inventors: Woei-Cherng Shyu, Shinn-Zong Lin, Hsiao-Jung Wang, Karl K. Johe
  • Synthesis of a neurostimulative piperazine
    Patent number: 9481649
    Abstract: The invention describes an improved synthesis for piperazine derivatized with nicotinic acid and a benzyl moiety. The product compounds are useful for treatment of neurological conditions.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: November 1, 2016
    Assignee: NEURALSTEM, INC.
    Inventors: Sripathy Venkatraman, Syed Mahmood, Bingidimi I. Mobele, Olga Lapina, Kellie Vercoe, Ying Li, Jonathan Salsbury, Mark McLaws
  • Stable neural stem cell lines
    Patent number: 9465025
    Abstract: A systematic and efficient method for establishing stable neural stem cell lines and neuronal progenitor lines is described. The resulting cell lines provide robust, simple, and reproducible cultures of human and other mammalian neurons in commercially useful mass quantities while maintaining normal karyotypes and normal neuronal phenotypes.
    Type: Grant
    Filed: April 15, 2009
    Date of Patent: October 11, 2016
    Assignee: Neuralstem, Inc.
    Inventors: Renji Yang, Karl K. Johe
  • SYNTHESIS OF A NEUROSTIMULATIVE PIPERAZINE
    Publication number: 20160090358
    Abstract: The invention describes an improved synthesis for piperazine derivatized with nicotinic acid and a benzyl moiety. The product compounds are useful for treatment of neurological conditions.
    Type: Application
    Filed: December 9, 2015
    Publication date: March 31, 2016
    Applicant: NEURALSTEM, INC.
    Inventors: Sripathy VENKATRAMAN, Syed MAHMOOD, Bingidimi I. MOBELE, Olga LAPINA, Kellie VERCOE, Ying LI, Jonathan SALSBURY, Mark MCLAWS
  • Synthesis of a neurostimulative piperazine
    Patent number: 9278933
    Abstract: The invention describes an improved synthesis for piperazine derivatized with nicotinic acid and a benzyl moiety. The product compounds are useful for treatment of neurological conditions.
    Type: Grant
    Filed: August 24, 2010
    Date of Patent: March 8, 2016
    Assignee: NEURALSTEM, INC.
    Inventors: Sripathy Venkatraman, Syed Mahmood, Bingidimi I. Mobele, Olga Lapina, Kellie Vercoe, Ying Li, Jonathan Salsbury, Mark McLaws
  • Methods of treating ischemic spasticity
    Patent number: 9220730
    Abstract: The invention relates generally to methods of treating spasticity, rigidity, or muscular hyperactivity conditions by introducing a portion of an expanded population of neural stem cells into an area of a recipient spinal cord.
    Type: Grant
    Filed: May 9, 2013
    Date of Patent: December 29, 2015
    Assignees: Neuralstem, Inc., The Regents of the University of California
    Inventors: Karl K. Johe, Thomas G. Hazel, Martin Marsala, Osamu Kakinohana
  • SURVIVAL, DIFFERENTIATION AND STRUCTURAL INTEGRATION OF HUMAN NEURAL STEM CELLS GRAFTED INTO THE ADULT RAT SPINAL CORD
    Publication number: 20150086511
    Abstract: The present invention provides methods and compositions for treating spinal cord diseases and injuires. The methods involve transplanting neural stem cells which have been previously expanded in vitro into a patient such that the cells can ameliorate the disease or injury. The stem cells to be transplanted are derived from spinal cord tissue.
    Type: Application
    Filed: January 31, 2014
    Publication date: March 26, 2015
    Applicants: NEURALSTEM, INC., THE JOHNS HOPKINS UNIVERSITY
    Inventors: Vassilis E. Koliatsos, Jun Yan, Karl K. Johe
  • Compositions to effect neuronal growth
    Patent number: 8846914
    Abstract: Compositions containing neurogenic agents for inhibition of neuron death and inducing proliferation of neural cells are disclosed.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: September 30, 2014
    Assignee: Neuralstem, Inc.
    Inventors: Judith Kelleher-Andersson, Karl K. Johe